|
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792 |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Seagen (Inst) |
Research Funding - 4SC (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Ferring; Janssen; Pfizer; Roche |
Speakers' Bureau - Astellas Pharma; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; ipsen; Medac; Pfizer; Roche |
Research Funding - Roche/Genentech |
Travel, Accommodations, Expenses - Janssen medical Affairs |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; PAIGE.AI; Pfizer |
|
|
Honoraria - Astellas Pharma; AstraZeneca; ferring; Imvax; Janssen; Merck; Pfizer; Prokarium; Protara Therapeutics; Urogen pharma |
Research Funding - Epizyme; Merck Sharp & Dohme |
Patents, Royalties, Other Intellectual Property - NMIBC genetic classifier (Inst); TCGA Classifier (Inst) |
Other Relationship - Olympus |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Nippon Kayaku; Ono Pharmaceutical |
Research Funding - Astellas Pharma; Chugai Pharma; Johnson & Johnson |
|
|
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I) |
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I) |
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I) |
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; Daichi-Sanchyo; DYANIA HEALTH; EMD Serono; EMD Serono; Exelixis; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen |
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst) |
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I) |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Merck; Novartis |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Merck; Novartis |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Merck; Seagen |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche |